Can a common blood pressure pill prevent heart attacks after kidney failure in the ICU?
NCT ID NCT05272878
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether irbesartan, a blood pressure medication, can reduce the risk of major heart problems and kidney disease in people who had acute kidney injury while in the intensive care unit (ICU). About 500 adults aged 18-75 will take either irbesartan or a placebo for 12 months after leaving the ICU. The goal is to see if this drug can improve long-term outcomes for these high-risk patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Irbesartan (a blood pressure medication)
What this could lead to
If it works, this could point toward a simple, widely available treatment to reduce heart attacks, strokes, and kidney failure after a serious kidney injury in the ICU.
What could go wrong
This is a phase 3 trial, but it is still early to know if irbesartan will help or cause side effects like low blood pressure. Results may not apply to all kidney injury patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Lariboisière
Paris, 75010, France